LICENSING DISPUTES IN GENE TECHNOLOGIES

1. INTRODUCTION

Licensing disputes in gene technologies arise when disagreements occur over the ownership, authorised use, commercial exploitation, transfer, or payment for genetic inventions and biotechnology platforms. These disputes may involve patented DNA sequences, gene-editing technologies, genetically modified crops, CRISPR-based systems, gene therapies, diagnostic methods, research tools, and proprietary biological materials.

A gene-technology licence typically grants permission to use specified intellectual property or technical resources subject to contractual conditions. Disputes commonly concern royalty payments, patent validity, licence termination, sublicensing, research rights, confidentiality, ownership of improvements, regulatory compliance, and restrictions on competing technologies.

In India, these disputes are principally governed by the Patents Act, 1970, the Indian Contract Act, 1872, applicable intellectual-property principles, and, where relevant, the Competition Act, 2002, the Protection of Plant Varieties and Farmers' Rights Act, 2001, and environmental and biotechnology regulations. The legal outcome depends on the licensed subject matter, the agreement's wording, the validity and scope of the underlying rights, and applicable statutory restrictions.

2. LEGAL FRAMEWORK GOVERNING GENE-TECHNOLOGY LICENSING

A. PATENTS ACT, 1970

Sections 48 and 68 are particularly relevant. Section 48 describes the rights of a patentee, subject to the Act, while Section 68 requires patent assignments, licences, and other interests to be in writing and duly executed to be valid. Sections 64 and 107 provide, respectively, for grounds of patent revocation and relevant defences in infringement proceedings.

Section 3(j) excludes plants and animals in whole or in part, other than microorganisms, as well as essentially biological processes for the production or propagation of plants and animals, from patentability. Its application to a particular genetic invention depends on the claims and relevant legal interpretation. A licence cannot create enforceable patent rights over subject matter that the law excludes from patent protection.

B. INDIAN CONTRACT ACT, 1872

Licence agreements must satisfy applicable contractual requirements, including lawful consideration, consent, and lawful object. Sections 37 and 39 address performance of contractual obligations and refusal to perform a promise in its entirety, while Section 73 provides for compensation for loss or damage caused by breach, subject to its conditions.

The precise consequences of termination depend on the agreement, the nature of the breach, applicable statutory provisions, and any available remedies. A licensor cannot necessarily terminate a licence in disregard of contractual notice, cure periods, or mandatory legal restrictions.

C. COMPETITION LAW

The Competition Act, 2002, may apply where licensing arrangements involve abuse of dominance, anti-competitive agreements, or other conduct prohibited by the Act. A patent or other intellectual-property right does not automatically immunise every licensing restriction from competition scrutiny. However, a royalty dispute or restrictive term is not, by itself, proof of a competition-law violation.

D. BIOTECHNOLOGY AND BIOSAFETY REGULATION

Where licensed technology involves genetically modified organisms or regulated biological research, separate environmental, biosafety, clinical, or other regulatory permissions may be required. A private licence grants contractual or intellectual-property permission only to the extent provided by law; it does not replace statutory approval for research, manufacture, clinical use, or environmental release.

3. COMMON TYPES OF LICENSING DISPUTES

A. ROYALTY AND LICENCE-FEE DISPUTES: Parties may disagree over upfront payments, recurring royalties, milestone payments, commercial sales calculations, or royalty adjustments imposed by government policy. The agreement should specify the payment formula, audit rights, reporting duties, and consequences of non-payment.

B. PATENT VALIDITY AND SCOPE: A licensee may challenge whether the licensed gene sequence, gene-editing method, vector, or related invention is patentable or falls within the claims of the patent. A patent licence cannot expand the statutory scope of the underlying patent.

C. TERMINATION AND CONTINUED USE: Disputes arise when a licensor terminates an agreement for alleged breach, while the licensee claims that termination was unlawful or that rights survive under the contract. Continued use after valid termination may expose the licensee to contractual or infringement claims, depending on the surviving rights and applicable law.

D. SUBLICENSING AND OWNERSHIP OF IMPROVEMENTS: Disagreements may concern whether a licensee can grant rights to another company, transfer technology to an affiliate, or retain ownership of improvements developed using licensed technology. The agreement should clearly distinguish background intellectual property from newly created inventions.

E. RESTRICTIVE LICENSING CONDITIONS: Exclusive licences, restrictions on competing technologies, field-of-use limitations, and royalty structures may be challenged where they violate applicable competition law. Whether a restriction is unlawful depends on the market, the parties' position, the agreement's effects, and the relevant statutory provisions.

4. IMPORTANT CASE LAWS

1. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) — Direct authority on gene-technology licensing disputes. The Supreme Court of India considered a dispute involving Monsanto's patented Bt cotton technology, sub-licence agreements, royalty or trait-value payments, termination, and the interaction between patent law and plant-variety legislation. The Court set aside the Delhi High Court Division Bench's decision and restored the matter for determination through appropriate proceedings. It did not finally decide the patentability question under Section 3(j). The case demonstrates that disputes over gene-technology royalties, licence termination, and patent validity may require detailed evidence and cannot always be resolved through summary proceedings.

2. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (Delhi High Court, 2018) — Direct authority at the appellate stage. The Division Bench considered whether the licensed Bt cotton technology fell within the patentability exclusions under Section 3(j) and examined the relationship between patent rights and plant-variety protection. The Supreme Court subsequently set aside this decision in 2019. Consequently, the High Court's conclusions must not be treated as the final determination of the patentability issue.

3. Mahyco Monsanto Biotech (India) Pvt. Ltd. v. Competition Commission of India (Delhi High Court, 2020) — Direct authority on competition scrutiny of gene-technology licensing. The dispute concerned allegations about royalties and restrictive conditions in sublicensing Bt cotton technology. The High Court upheld the Competition Commission of India's ability to investigate the allegations notwithstanding the existence of the patent-law framework. The decision illustrates that patent licensing practices may be subject to competition-law scrutiny in addition to intellectual-property rules.

4. Bayer Corporation v. Union of India (Bombay High Court, 2014) — Analogous authority on compulsory licensing. The litigation concerned Bayer's challenge to India's compulsory licence for the cancer medicine Nexavar, granted to Natco Pharma under Section 84 of the Patents Act. The dispute illustrates that patent exclusivity and licensing rights remain subject to statutory conditions, including public-interest considerations. Although the case concerned pharmaceuticals rather than gene technologies, its principles may be relevant to licensing disputes involving patented biotechnology products.

5. Novartis AG v. Union of India (2013) — Analogous authority on biotechnology-related patentability limits. The Supreme Court examined Section 3(d) of the Patents Act in relation to a pharmaceutical invention. The judgment emphasised that patent protection depends on compliance with statutory patentability requirements. In gene-technology licensing disputes, the broader principle is that contractual rights cannot cure a failure to satisfy applicable patentability requirements. The case did not directly concern a gene-technology licence.

6. Telefonaktiebolaget LM Ericsson v. Competition Commission of India (Delhi High Court, 2016) — Analogous authority on competition law and intellectual-property rights. The litigation concerned allegations of abuse of dominance in the licensing of standard-essential patents. The court's approach to the relationship between patent rights and competition-law oversight is relevant by analogy to biotechnology licences where royalty structures, exclusivity, or restrictive terms are challenged.

7. Competition Commission of India v. Bharti Airtel Ltd. (2018) — Analogous authority on concurrent regulatory jurisdiction. The Supreme Court considered the relationship between the Competition Commission and a sector-specific regulator. The judgment is relevant where gene-technology licensing disputes involve multiple authorities with different statutory responsibilities. The sequence of proceedings may depend on the nature of the technical issue and the regulator's statutory role.

These decisions should be read according to their actual holdings. Monsanto v. Nuziveedu is the most directly relevant authority among them because it concerned gene technology, sublicensing, royalty disputes, and patent validity.

5. REMEDIES AND ENFORCEMENT

Depending on the dispute, the parties may seek:

Declaratory relief: A determination of the parties' contractual rights, the scope of the licence, or the legal status of the patent.

Injunctions: Orders restraining unauthorised use, disclosure, transfer, or commercial exploitation of protected technology, subject to applicable legal requirements.

Damages and accounts: Compensation for established contractual loss or infringement, where legally available.

Termination or specific performance: Remedies determined by the agreement, applicable contract law, and statutory restrictions.

Patent revocation or validity proceedings: Challenges under the Patents Act where recognised grounds exist.

Competition-law proceedings: Investigation and remedies where the licensing arrangement may violate the Competition Act.

Arbitration or mediation: Alternative dispute-resolution mechanisms where the agreement and applicable law permit them.

The parties should also consider regulatory permissions separately. A successful contractual claim does not automatically authorise the research, clinical use, manufacture, or environmental release of a genetically modified organism.

6. PRACTICAL COMPLIANCE REQUIREMENTS

Organisations entering gene-technology licences should:

Verify ownership, validity, territorial coverage, and remaining term of relevant intellectual-property rights.

Define the licensed genes, constructs, platforms, materials, methods, and permitted applications precisely.

Establish clear royalty formulas, audit rights, reporting duties, and payment deadlines.

Specify sublicensing rights, assignment restrictions, and approval requirements for affiliates.

Allocate ownership of improvements, derivative inventions, and jointly developed technology.

Establish confidentiality, biological-material handling, and research-data protection obligations.

Define breach procedures, notice requirements, cure periods, and termination consequences.

Address applicable competition-law and government price-control requirements.

Specify dispute-resolution procedures, governing law, jurisdiction, and interim-relief options.

Confirm that independent biosafety, environmental, clinical, and other statutory approvals remain in place.

7. CONCLUSION

Licensing disputes in gene technologies involve the interaction of intellectual-property rights, contractual obligations, competition law, and biotechnology regulation. The central issues commonly concern royalty payments, patent validity, licence termination, sublicensing, ownership of improvements, and restrictions on commercial use.

Indian decisions, particularly Monsanto Technology LLC v. Nuziveedu Seeds Ltd., demonstrate that gene-technology licensing disputes may involve complex questions of patent scope, statutory exclusions, contractual performance, and regulatory policy. Courts must examine the relevant agreement, patent claims, technical evidence, and applicable legislation rather than assume that either patent ownership or a licence agreement resolves every issue.

A well-drafted licence should define the permitted technology and uses, payment obligations, ownership of improvements, termination procedures, and dispute-resolution mechanisms. Ultimately, lawful licensing requires both enforceable contractual rights and compliance with the statutory limits governing patents, competition, and biotechnology activities.